Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Open in Screener

HLXB

Helix Acquisition Corp. II

Jan 30 • 04:00PM ET

10.70

Dollar change -0.00
Percentage change -0.00	%

Financial • Shell Companies • USA • NASD

Index	-	P/E	44.94	EPS (ttm)	0.24	Insider Own	26.79%	Shs Outstand	18.91M	Perf Week	1.81%
Market Cap	251.55M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	17.21M	Perf Month	2.39%
Income	5.60M	PEG	-	EPS next Q	-	Inst Own	69.65%	Short Float	0.03%	Perf Quarter	2.88%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	0.30	Perf Half Y	3.98%
Book/sh	7.94	P/B	1.35	EPS next Y	-	ROA	-	Short Interest	0.01M	Perf Year	-
Cash/sh	0.08	P/C	140.53	EPS next 5Y	-	ROE	-	52W Range	10.03 - 11.59	Perf YTD	1.90%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	3.00%	52W High	-7.68%	Beta	-
Dividend TTM	-	Quick Ratio	16.12	Sales past 5Y	0.00%	Gross Margin	-	52W Low	6.68%	ATR (14)	0.19
Dividend Ex-Date	-	Current Ratio	16.12	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	52.23	Volatility	1.11% 1.65%
Employees	-	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	-	Target Price	-
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	49700.00%	Payout	-	Rel Volume	0.02	Prev Close	10.70
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	16.70K	Price	10.70
SMA20	0.23%	SMA50	1.44%	SMA200	2.90%	Trades		Volume	287	Change	-0.00%

Feb-29-24 03:01AM	5 Stocks With Heavy Insider Buying In 2024 (Insider Monkey)
Feb-14-24 07:30AM	Helix Acquisition Corp. II Announces Closing of $184 Million Initial Public Offering, Including the Full Exercise of the Underwriter's Option to Purchase Additional Shares (Business Wire)
Feb-09-24 07:30AM	Helix Acquisition Corp. II Announces Pricing of Upsized $160 Million Initial Public Offering (Business Wire)

Helix Acquisition Corp. II operates as a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was formed on June 15, 2021 and is headquartered in Boston, MA.

Dollar change +1.06
Percentage change 2.30	%

MLTX MoonLake Immunotherapeutics daily Stock Chart

Peers: AMGN VRTX REGN ALNY BIIB BMRN GILD INCY SRPT BLUE

| Held by: VHT SBIO MSSM NUSC ONEQ ESML VT GURU FMED FHLC

Index	-	P/E	-	EPS (ttm)	-1.29	Insider Own	16.40%	Shs Outstand	63.05M	Perf Week	0.51%
Market Cap	3.01B	Forward P/E	-	EPS next Y	-2.77	Insider Trans	-17.16%	Shs Float	52.72M	Perf Month	-14.90%
Income	-80.77M	PEG	-	EPS next Q	-0.62	Inst Own	95.20%	Short Float	14.80%	Perf Quarter	-1.94%
Sales	0.00M	P/S	-	EPS this Y	-144.90%	Inst Trans	-2.19%	Short Ratio	24.48	Perf Half Y	14.20%
Book/sh	7.74	P/B	6.09	EPS next Y	-54.72%	ROA	-15.86%	Short Interest	7.80M	Perf Year	-19.00%
Cash/sh	7.73	P/C	6.10	EPS next 5Y	-	ROE	-17.69%	52W Range	37.55 - 64.98	Perf YTD	-12.98%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-16.48%	52W High	-27.49%	Beta	1.28
Dividend TTM	-	Quick Ratio	25.51	Sales past 5Y	0.00%	Gross Margin	-	52W Low	25.49%	ATR (14)	2.72
Dividend Ex-Date	-	Current Ratio	25.51	EPS Y/Y TTM	-36.77%	Oper. Margin	-	RSI (14)	47.42	Volatility	4.56% 6.02%
Employees	50	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	81.67
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-219.53%	Payout	-	Rel Volume	0.98	Prev Close	46.06
Sales Surprise	-	EPS Surprise	-28.59%	Sales Q/Q	-	Earnings	Nov 07 BMO	Avg Volume	318.72K	Price	47.12
SMA20	-0.52%	SMA50	-6.94%	SMA200	0.63%	Trades		Volume	311,428	Change	2.30%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-17-25	Upgrade	Goldman	Neutral → Buy	$62 → $82
Nov-05-24	Resumed	Wedbush	Outperform	$92 → $73
Aug-26-24	Downgrade	Wolfe Research	Outperform → Peer Perform
Jun-25-24	Initiated	Oppenheimer	Outperform	$104
Apr-02-24	Initiated	Goldman	Neutral	$62
Feb-15-24	Initiated	Wolfe Research	Outperform	$77
Dec-08-23	Initiated	Citigroup	Buy	$72
Nov-02-23	Initiated	Stifel	Buy	$74
Sep-14-23	Downgrade	Bryan Garnier	Buy → Neutral
Aug-31-23	Initiated	Needham	Buy	$76
Jun-15-23	Initiated	Barclays	Equal Weight	$28
May-01-23	Initiated	Guggenheim	Buy	$51
Mar-22-23	Initiated	Wedbush	Outperform	$33
Mar-09-23	Initiated	BTIG Research	Buy	$36
Feb-14-23	Initiated	Cantor Fitzgerald	Overweight	$23
Feb-02-23	Initiated	Bryan Garnier	Buy	$22
Nov-11-22	Initiated	Jefferies	Buy	$16
Aug-25-22	Initiated	SVB Leerink	Outperform	$17
Jul-21-22	Initiated	H.C. Wainwright	Buy	$28
Jul-07-22	Initiated	Cowen	Outperform

Show Previous Ratings

Jan-10-25 07:15AM	MoonLake Immunotherapeutics price target raised to $81 from $71 at BTIG (TipRanks)
Jan-08-25 07:00AM	MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody sonelokimab (GlobeNewswire)
Nov-13-24 08:00AM	MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody sonelokimab in patients with active psoriatic arthritis (GlobeNewswire)
Nov-07-24 07:00AM	MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Oct-08-24 09:11PM	Biotechnology Value Fund L.P. Reduces Stake in MoonLake Immunotherapeutics (GuruFocus.com)
11:55PM	Loading…
Sep-24-24 11:55PM	Is MoonLake Immunotherapeutics (MLTX) the Best Guru Stock To Buy Now? (Insider Monkey) -6.36%
Sep-23-24 02:44AM	MoonLake Immunotherapeutics (MLTX): Short Seller Sentiment is Bearish On This ADR Stock (Insider Monkey)
Sep-09-24 07:00AM	MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11 (GlobeNewswire)
Aug-27-24 08:21PM	MoonLake Immunotherapeutics (MLTX): One of Oppenheimers Top Stock Picks For the Next 12 Months (Insider Monkey)
Aug-07-24 08:00AM	MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11 (GlobeNewswire)
Jun-10-24 08:00AM	MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody sonelokimab in Psoriatic Arthritis (GlobeNewswire)
May-16-24 08:00AM	MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (GlobeNewswire)
May-07-24 09:02PM	MoonLake Immunotherapeutics Reports Q1 2024 Financial Outcomes (GuruFocus.com)
01:53PM	MLTX Stock Earnings: MoonLake Misses EPS for Q1 2024 (InvestorPlace)
10:15AM	MoonLake Immunotherapeutics Q1 Net Loss Widens (MT Newswires)
08:00AM	Loading…
08:00AM	MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Apr-10-24 07:00AM	MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions (GlobeNewswire)
Mar-11-24 04:25PM	MoonLake Jumps After Arthritis Drug Tops AbbVie Blockbuster Humira In A Key Test (Investor's Business Daily)
Mar-10-24 12:00PM	MoonLake announces significant improvements with Nanobody sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day (GlobeNewswire)
Mar-04-24 08:00AM	MoonLake Immunotherapeutics to present MIRA trial data of Nanobody sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024 (GlobeNewswire)
Mar-01-24 12:38AM	Insider Sell: CEO Santos da Silva Jorge Sells 123,615 Shares of MoonLake Immunotherapeutics (MLTX) (GuruFocus.com) +5.56%
Feb-29-24 08:00AM	MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10 (GlobeNewswire) -15.09%
Feb-26-24 08:00AM	MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody sonelokimab (SLK) in Hidradenitis Suppurativa (HS) (GlobeNewswire)
Feb-20-24 11:44PM	Insider Sell: CEO Santos da Silva Jorge Sells 60,000 Shares of MoonLake Immunotherapeutics (GuruFocus.com) -7.88%
Jan-11-24 09:55AM	Wall Street Analysts Believe MoonLake Immunotherapeutics (MLTX) Could Rally 26.97%: Here's is How to Trade (Zacks)
Jan-10-24 08:42AM	Is MoonLake Immunotherapeutics (MLTX) Stock a Solid Choice Right Now? (Zacks)
Dec-22-23 03:01PM	CFO Matthias Bodenstedt Sells 100,000 Shares of MoonLake Immunotherapeutics (GuruFocus.com)
Nov-14-23 12:13PM	MoonLake Immunotherapeutics (MLTX) Posts Q3 2023 Results: Clinical Progress Amid Controlled Expenses (GuruFocus.com)
08:00AM	MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Nov-06-23 04:03PM	Why Former Highflier MoonLake Plummeted 29% After A Recent Run (Investor's Business Daily) -29.11% +15.98%
09:46AM	Loading…
09:46AM	Top-Rated MoonLake Stock Crashes On Mixed Test Results For Arthritis Drug (Investor's Business Daily)
Nov-05-23 11:00AM	MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody sonelokimab in active psoriatic arthritis (GlobeNewswire)
Oct-26-23 10:33AM	12 Best Performing NASDAQ Stocks in 2023 (Insider Monkey)
Oct-20-23 01:22PM	12 Best Performing Biotech Stocks in 2023 (Insider Monkey)
Oct-16-23 04:30PM	MoonLake Immunotherapeutics' Lead Skin Disorder Candidate Continues to Deliver on Best-Efficacy Profile: Analyst (Benzinga) +10.72% -5.20%
04:04PM	Why Top-Notch MoonLake Surged 11% And Almost Broke Out (Investor's Business Daily)
10:41AM	Why Top 1% Biotech MoonLake Just Surged Within Striking Distance Of A Breakout (Investor's Business Daily)
Oct-15-23 09:03AM	MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa (GlobeNewswire)
Oct-11-23 10:15AM	MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress (GlobeNewswire) -7.06%
Oct-04-23 07:01AM	Phase 2 MIRA primary analysis trial results (12-week) for MoonLake's Nanobody sonelokimab in hidradenitis suppurativa to be presented at a late-breaking session at the European Academy of Dermatology and Venereology Congress (GlobeNewswire)
Sep-27-23 09:24PM	7 Strong Buy Biotech Stocks to Rejuvenate Your Portfolio (InvestorPlace)
Sep-18-23 05:09PM	These 7 Stocks Are Outperforming Nvidia In 2023 (Investor's Business Daily)
Sep-13-23 09:45AM	ACELYRIN (SLRN) Fails to Meet Goal in HS Study, Stock Down 54% (Zacks)
Sep-12-23 04:07PM	The Surprising Acelyrin News That Sent Rival MoonLake, A Top 1% Stock, Soaring 10% (Investor's Business Daily) +9.88%
11:40AM	Why Shares of MoonLake Immunotherapeutics Are Rising Tuesday (Motley Fool)
Sep-06-23 07:00AM	MoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11 (GlobeNewswire)
Sep-01-23 02:00PM	Top Growth Stocks for September 2023 (Investopedia) -6.32%
11:30AM	Top Stocks for September 2023 (Investopedia)
Aug-31-23 09:53AM	Palantir downgraded, Shopify upgraded: Wall Street's top analyst calls (The Fly)
08:30AM	The 7 Most Promising Momentum Stocks to Own Now (InvestorPlace)
Aug-16-23 03:12PM	15 Best Performing Stocks in the Last 3 Months (Insider Monkey)
Aug-15-23 07:00AM	Get In on This Skin Disease Drug Before Big Pharma Does (The Wall Street Journal)
Aug-10-23 07:00AM	MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Jul-25-23 08:00AM	MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readouts (GlobeNewswire)
Jul-14-23 03:38PM	Exclusive-MoonLake Immunotherapeutics explores sale-sources (Reuters) +8.39%
Jul-03-23 09:45AM	MoonLake Immunotherapeutics' (NASDAQ:MLTX) high hedge funds ownership speaks for itself as stock continues to impress, up 11% over last week (Simply Wall St.)
Jun-29-23 02:41PM	Why MoonLake Immunotherapeutics Stock Skyrocketed This Week (Motley Fool)
Jun-28-23 05:00AM	MoonLake Immunotherapeutics Announces Pricing of $400 Million Upsized Public Offering of Class A Ordinary Shares (GlobeNewswire)
Jun-27-23 06:56PM	Why MoonLake Immunotherapeutics Was Such a Healthy Stock Today (Motley Fool) +12.71%
Jun-26-23 04:07PM	Why Mutual Fund Darling And Top 1% Stock MoonLake Just Catapulted To A Record (Investor's Business Daily) +77.55%
04:01PM	MoonLake Immunotherapeutics Announces Proposed Underwritten Public Offering (GlobeNewswire)
02:36PM	Why Shares of MoonLake Immunotherapeutics Skyrocketed Monday (Motley Fool)
09:01AM	Lucid Stock Moved Into the Fast Lane, but This Nasdaq Biotech Was Monday's Big Winner (Motley Fool)
Jun-25-23 09:00AM	MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa (GlobeNewswire)
May-26-23 08:50AM	MoonLake Immunotherapeutics (MLTX) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
May-14-23 09:43AM	TipRanks Perfect 10 List: 3 Top-Rated Stocks That Tick All the Right Boxes (TipRanks)
May-12-23 07:45AM	MoonLake Immunotherapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire)
May-11-23 08:32AM	Why MoonLake (MLTX) Might Surprise This Earnings Season (Zacks) -5.45%
May-10-23 08:50AM	Here's Why Momentum in MoonLake Immunotherapeutics (MLTX) Should Keep going (Zacks)
May-03-23 06:45AM	MoonLake Immunotherapeutics and SHL Medical collaborate to jointly develop an autoinjector for sonelokimab supply (GlobeNewswire) +7.55%
Apr-24-23 08:50AM	MoonLake Immunotherapeutics (MLTX) is on the Move, Here's Why the Trend Could be Sustainable (Zacks) +10.08%
Apr-19-23 08:16AM	MoonLake Immunotherapeutics to host Capital Markets Day in New York and virtually today (GlobeNewswire)
Apr-05-23 12:00PM	What Makes MoonLake Immunotherapeutics (MLTX) a New Buy Stock (Zacks) +6.84%
Mar-20-23 07:45AM	MoonLake Immunotherapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides a Business Update (GlobeNewswire) -7.87%
Feb-14-23 01:02PM	Cantor On MoonLake Immunotherapeutics - Initiates On Inexpensive Valuation, Strong Catalyst Path (Benzinga) +8.16%
Feb-02-23 08:00AM	MoonLake Immunotherapeutics completes patient enrollment and randomization ahead of schedule in a Phase 2 trial of the Nanobody® sonelokimab in moderate-to-severe hidradenitis suppurativa (GlobeNewswire)
Dec-14-22 08:00AM	MoonLake Immunotherapeutics screens first patient in Phase 2 study of the Nanobody® sonelokimab in active psoriatic arthritis (GlobeNewswire)
Nov-14-22 08:00AM	MoonLake Immunotherapeutics Reports Third Quarter 2022 Financial Results and Provides Recent Business Update (GlobeNewswire)
Sep-26-22 10:57AM	FDA Clears MoonLake's Nanobody Study For Arthritis Patients (Benzinga)
08:00AM	MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® sonelokimab in patients with active psoriatic arthritis (GlobeNewswire)
Jul-26-22 08:00AM	MoonLake Immunotherapeutics signs development and manufacturing agreement with Vetter Pharma International GmbH (GlobeNewswire) +13.31%
Jul-25-22 10:11AM	Do Insiders Own Lots Of Shares In MoonLake Immunotherapeutics (NASDAQ:MLTX)? (Simply Wall St.)
May-12-22 07:00AM	MoonLake Immunotherapeutics starts Phase 2 trial of the Nanobody® Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (GlobeNewswire)

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BVF PARTNERS L P/IL	Director	Oct 04 '24	Sale	50.00	2,000,000	100,003,200	1,287,768	Oct 08 06:50 PM
Sturge Simon	Director	Oct 04 '24	Sale	53.72	171,000	9,186,120	171,980	Oct 08 04:01 PM
Santos da Silva Jorge	Chief Executive Officer	Feb 27 '24	Sale	55.00	62,810	3,454,550	3,043,619	Feb 29 07:56 PM
Santos da Silva Jorge	Chief Executive Officer	Feb 28 '24	Sale	55.00	56,065	3,083,575	2,987,554	Feb 29 07:56 PM
Santos da Silva Jorge	Chief Executive Officer	Feb 29 '24	Sale	55.89	4,740	264,919	2,982,814	Feb 29 07:56 PM
Reich Kristian	Chief Scientific Officer	Feb 28 '24	Sale	55.00	31,910	1,755,050	2,925,573	Feb 29 07:53 PM
Reich Kristian	Chief Scientific Officer	Feb 27 '24	Sale	55.00	29,491	1,622,005	2,957,483	Feb 29 07:53 PM
Reich Kristian	Chief Scientific Officer	Feb 27 '24	Sale	55.00	29,431	1,618,705	70,071	Feb 29 07:53 PM
Reich Kristian	Chief Scientific Officer	Feb 28 '24	Sale	55.00	28,090	1,544,950	41,981	Feb 29 07:53 PM
Santos da Silva Jorge	Chief Executive Officer	Feb 21 '24	Sale	55.27	1,125	62,179	3,106,429	Feb 23 04:48 PM
Reich Kristian	Chief Scientific Officer	Feb 20 '24	Sale	57.45	10,000	574,500	2,987,483	Feb 22 06:32 PM
Reich Kristian	Chief Scientific Officer	Feb 20 '24	Sale	57.43	10,000	574,300	100,071	Feb 22 06:32 PM
Reich Kristian	Chief Scientific Officer	Feb 21 '24	Sale	55.30	569	31,466	99,502	Feb 22 06:32 PM
Reich Kristian	Chief Scientific Officer	Feb 21 '24	Sale	55.31	509	28,153	2,986,974	Feb 22 06:32 PM
Santos da Silva Jorge	Chief Executive Officer	Feb 15 '24	Sale	60.18	20,000	1,203,600	3,147,554	Feb 20 06:36 PM
Santos da Silva Jorge	Chief Executive Officer	Feb 16 '24	Sale	60.15	20,000	1,203,000	3,127,554	Feb 20 06:36 PM
Santos da Silva Jorge	Chief Executive Officer	Feb 20 '24	Sale	57.44	20,000	1,148,800	3,107,554	Feb 20 06:36 PM
Reich Kristian	Chief Scientific Officer	Feb 14 '24	Sale	62.43	10,000	624,300	130,071	Feb 16 06:02 PM
Reich Kristian	Chief Scientific Officer	Feb 14 '24	Sale	62.42	10,000	624,200	3,017,483	Feb 16 06:02 PM
Reich Kristian	Chief Scientific Officer	Feb 15 '24	Sale	60.17	10,000	601,700	3,007,483	Feb 16 06:02 PM
Reich Kristian	Chief Scientific Officer	Feb 15 '24	Sale	60.16	10,000	601,600	120,071	Feb 16 06:02 PM
Reich Kristian	Chief Scientific Officer	Feb 16 '24	Sale	60.15	10,000	601,500	2,997,483	Feb 16 06:02 PM
Reich Kristian	Chief Scientific Officer	Feb 16 '24	Sale	60.15	10,000	601,500	110,071	Feb 16 06:02 PM

Open in Screener

BMEA

Biomea Fusion Inc

Jan 30 • 04:00PM ET

4.25

Dollar change +0.03
Percentage change 0.71	%

Healthcare • Biotechnology • USA • NASD

BMEA Biomea Fusion Inc daily Stock Chart

Peers: REPL BNTC IGMS NRIX KURA FATE MGTX GOSS BLUE SYBX

| Held by: IWM VTI VXF IWO IBB VTWO SCHA VHT IWC VTWG

Index	RUT	P/E	-	EPS (ttm)	-4.00	Insider Own	12.70%	Shs Outstand	36.24M	Perf Week	-5.13%
Market Cap	154.02M	Forward P/E	-	EPS next Y	-3.55	Insider Trans	0.22%	Shs Float	31.63M	Perf Month	6.25%
Income	-144.01M	PEG	-	EPS next Q	-0.91	Inst Own	65.91%	Short Float	38.83%	Perf Quarter	-65.75%
Sales	0.00M	P/S	-	EPS this Y	-13.01%	Inst Trans	-0.53%	Short Ratio	13.92	Perf Half Y	-20.11%
Book/sh	2.10	P/B	2.03	EPS next Y	8.65%	ROA	-85.85%	Short Interest	12.28M	Perf Year	-76.44%
Cash/sh	2.43	P/C	1.75	EPS next 5Y	1.36%	ROE	-104.51%	52W Range	3.61 - 20.21	Perf YTD	9.54%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-204.86%	ROI	-173.82%	52W High	-78.97%	Beta	-0.36
Dividend TTM	-	Quick Ratio	3.39	Sales past 5Y	0.00%	Gross Margin	-	52W Low	17.73%	ATR (14)	0.33
Dividend Ex-Date	-	Current Ratio	3.39	EPS Y/Y TTM	-19.65%	Oper. Margin	-	RSI (14)	43.27	Volatility	5.59% 7.18%
Employees	103	Debt/Eq	0.13	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.40	Target Price	27.10
Option/Short	Yes / Yes	LT Debt/Eq	0.09	EPS Q/Q	-13.52%	Payout	-	Rel Volume	0.37	Prev Close	4.22
Sales Surprise	-	EPS Surprise	3.65%	Sales Q/Q	-	Earnings	Oct 29 AMC	Avg Volume	882.37K	Price	4.25
SMA20	3.22%	SMA50	-16.29%	SMA200	-43.81%	Trades		Volume	324,072	Change	0.71%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-09-24	Initiated	Edward Jones	Buy	$128
Sep-27-24	Upgrade	Truist	Hold → Buy	$54
Sep-27-24	Upgrade	Rodman & Renshaw	Neutral → Buy	$18
Aug-29-24	Initiated	CapitalOne	Overweight	$25
Jun-11-24	Downgrade	Truist	Buy → Hold
Jun-07-24	Downgrade	Barclays	Overweight → Equal Weight	$30 → $5
Apr-02-24	Downgrade	JP Morgan	Overweight → Neutral	$51 → $14
Feb-06-24	Initiated	Truist	Buy	$55
Jul-27-23	Initiated	Scotiabank	Sector Outperform	$41
Jun-26-23	Downgrade	Jefferies	Buy → Hold
May-12-23	Initiated	Barclays	Overweight	$50
Mar-29-23	Reiterated	Oppenheimer	Outperform	$25 → $47
Mar-28-23	Reiterated	H.C. Wainwright	Buy	$37 → $44
Feb-24-23	Initiated	Citigroup	Buy	$20
Jun-02-22	Resumed	H.C. Wainwright	Buy	$16
Jan-12-22	Initiated	H.C. Wainwright	Buy	$13
Dec-17-21	Initiated	Oppenheimer	Outperform	$22
May-11-21	Initiated	Piper Sandler	Overweight	$27
May-11-21	Initiated	JP Morgan	Overweight	$26
May-11-21	Initiated	Jefferies	Buy	$26

Show Previous Ratings

Jan-13-25 09:00AM	Biomea Fusion to Become a Diabetes and Obesity Medicines Company (GlobeNewswire)
09:00AM	Biomea Fusion to Become a Diabetes & Obesity Medicines Company (GlobeNewswire)
Jan-07-25 09:00AM	Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study (GlobeNewswire)
Jan-06-25 09:04AM	Heres Why Biomea Fusion, Inc. (NASDAQ:BMEA) Is Among the Best Diabetes Stocks to Buy Under $10 (Insider Monkey) +5.09%
07:00AM	Biomea Fusion to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
10:41AM	Loading…
Dec-17-24 10:41AM	Why Is Diabetes-Drug Developer Biomea Fusion Stock Trading Lower On Tuesday? (Benzinga) -20.68%
08:10AM	Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (GlobeNewswire)
Dec-16-24 06:15PM	Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D) (GlobeNewswire)
Dec-12-24 05:02PM	Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC) (GlobeNewswire) -5.54%
05:02PM	Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) (GlobeNewswire)
Dec-09-24 04:01PM	Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia (GlobeNewswire) -5.08%
Dec-06-24 08:00AM	Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia (GlobeNewswire)
Dec-02-24 04:05PM	Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.50%
Nov-18-24 08:00AM	Late-Breaker Oral Presentation Showing New Analysis from the Escalation Portion of COVALENT-111 Presented at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024) (GlobeNewswire)
Nov-01-24 04:05PM	Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
04:00PM	Loading…
Oct-30-24 04:00PM	Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate (GlobeNewswire) -14.26% -9.38%
Oct-29-24 04:46PM	Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights (GlobeNewswire)
Oct-21-24 09:00AM	Biomea Fusion Announces Approval of icovamenib as International Nonproprietary Name for BMF-219 (GlobeNewswire)
Oct-15-24 04:05PM	Biomea Fusion to Host Conference Call and Webcast on Wednesday, October 30th at 4:30 pm ET to Announce Our Lead Clinical Candidate, BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist and Preclinical Data Combining BMF-219 with a GLP-1 RA-Based Therapy (GlobeNewswire) +5.38%
Oct-10-24 08:57AM	Morning Movers: Arcadium Lithium surges after deal to be acquired (TipRanks)
Oct-07-24 09:00AM	Biomea Fusion to Present at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024) (GlobeNewswire)
Oct-01-24 09:00AM	Biomea Announces Formation of Global Scientific Advisory Board with 22 World-Renowned Diabetes Experts (GlobeNewswire) -5.94%
Sep-27-24 12:20PM	FDA Removes Clinical Hold On Biomea Fusion's Early-Stage Trials For Potential Diabetes Candidate (Benzinga)
11:13AM	Biomeas stock bounces back as FDA lifts clinical hold on diabetes trials (Pharmaceutical Technology)
Sep-26-24 02:00PM	FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials (GlobeNewswire) +9.12%
Aug-14-24 09:55AM	Wall Street Analysts Think Biomea Fusion (BMEA) Could Surge 317.86%: Read This Before Placing a Bet (Zacks)
Aug-01-24 04:05PM	Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-31-24 10:54PM	BMEA Stock Earnings: Biomea Fusion Beats EPS for Q2 2024 (InvestorPlace)
04:05PM	Biomea Fusion Reports Second Quarter 2024 Financial Results and Corporate Highlights (GlobeNewswire)
Jun-29-24 08:32PM	Biomea Fusion, Inc. (BMEA): Why Did Analysts Give This Biotech Penny Stock a Moderate Buy Rating? (Insider Monkey)
06:30PM	Loading…
06:30PM	10 Best Biotech Penny Stocks to Buy Now (Insider Monkey)
Jun-28-24 02:21AM	Why Are Hedge Funds Shorting Biomea Fusion, Inc. (BMEA)? (Insider Monkey)
Jun-26-24 11:08PM	What Is Short Selling In Stock Market? 15 Stocks Hedge Funds are Shorting (Insider Monkey) -14.59%
Jun-17-24 09:00AM	Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies (GlobeNewswire) -9.75%
Jun-11-24 11:34AM	Biomea Fusion, Inc. (NASDAQ:BMEA) Downgraded by Barclays (Insider Monkey)
09:06AM	Analysts on Wall Street Lower Ratings for These 10 Stocks (Insider Monkey)
Jun-07-24 04:23PM	Biomea Fusion Crashes 63% After FDA Puts Diabetes Treatment Studies On Hold (Investor's Business Daily) -63.27%
08:16AM	Why Is Biomea Fusion (BMEA) Stock Down 63% Today? (InvestorPlace)
07:22AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
06:17AM	Ride the Gamma Wave: 3 Stocks on the Verge of a Short Squeeze (InvestorPlace)
04:25AM	FDA places full clinical hold on Biomea Fusions diabetes trials of BMF-219 (Clinical Trials Arena)
Jun-06-24 04:05PM	Biomea Fusion Announces BMF-219 in Diabetes Placed on Clinical Hold (GlobeNewswire)
01:14PM	Short Squeeze Specialists: 3 Stocks With the Expertise to Defy Bearish Expectations (InvestorPlace)
Jun-03-24 04:05PM	Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-30-24 09:12AM	Biomea Fusion Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes (GlobeNewswire)
May-02-24 10:54PM	BMEA Stock Earnings: Biomea Fusion Misses EPS for Q1 2024 (InvestorPlace)
04:05PM	Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights (GlobeNewswire)
May-01-24 04:10PM	Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.73%
Apr-19-24 11:02AM	12 Most Shorted Stocks in 2024 (Insider Monkey)
Apr-01-24 04:10PM	Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -16.34%
01:52PM	BMEA Stock Earnings: Biomea Fusion Misses EPS for Q4 2023 (InvestorPlace)
09:02AM	Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219 (GlobeNewswire)
09:00AM	Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights (GlobeNewswire)
Mar-07-24 02:52PM	7 Short-Squeeze Stocks That Could Send the Bears Into Panic-Mode (InvestorPlace)
Mar-06-24 03:04AM	Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219's 28-Day Treatment Cycle, Supporting Improved Pancreatic Function (GlobeNewswire) -9.82%
Mar-01-24 04:16PM	Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-19-24 03:18PM	Feeling Shut Out? 3 Sizzling Stocks and the Pull-Back Prices to Watch For (InvestorPlace)
Feb-18-24 03:41PM	3 Speculative Stocks That Could Make Your February Unforgettable (InvestorPlace)
Feb-08-24 04:19PM	3 Long-Term Stocks to Buy on the Dip: February 2024 (InvestorPlace)
Jan-09-24 11:02AM	Biomea Fusion Highlights Recent Updates and Anticipated 2024 Corporate Milestones at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-08-24 09:00AM	Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase II Study (COVALENT-112) with BMF-219 (GlobeNewswire) +8.36%
Jan-02-24 04:05PM	Biomea Fusion to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-12-23 09:27AM	Biomea Fusion (BMEA) Stock Surges 41% in a Month: Here's Why (Zacks) +15.29%
Dec-11-23 09:25AM	Biomea Fusion Presents Achievement of Minimal Residual Disease Negativity (MRD-neg) in First Complete Responder from Ongoing Phase I Study (COVALENT-101) of BMF-219 in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) at the 2023 ASH Annual Meeting (GlobeNewswire) -30.31%
Dec-09-23 05:30PM	Biomea Fusion Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the 200 mg Dose Cohorts (GlobeNewswire)
Dec-08-23 09:00AM	Biomea Fusion Presents Long-Term Follow-Up Data Showing Improved Glycemic Control after 22 Weeks Off Treatment in Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes in a Poster Presentation at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) (GlobeNewswire) +12.38%
Dec-07-23 09:15AM	Biomea Fusion to Present Long-Term Follow-Up Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes and Results from Ex-Vivo Human Islet Experiments at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) (GlobeNewswire) -18.54%
Dec-05-23 08:30AM	Biomea Fusion Announces Health Canada Clearance of Clinical Trial Application (CTA) for BMF-219 in Type 1 Diabetes (GlobeNewswire)
Nov-27-23 08:30AM	Biomea Fusion Announces Acceptance of Three Abstracts for its Novel Menin Inhibitor Highlighting Durable Glycemic Control in Diabetes Patients at the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in 2024 (GlobeNewswire)
Nov-16-23 08:30AM	Biomea Fusion Abstract BMF-219: A Novel Therapeutic Agent to Reestablish Functional Beta Cells and Provide Long-term Glycemic Control' Selected as One of Six Oral Presentations at 21st World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (GlobeNewswire)
Nov-08-23 04:05PM	Biomea Fusion to Present New Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) (GlobeNewswire) -5.40%
Nov-02-23 09:05AM	Biomea Fusion Announces Two Poster Presentations at Upcoming ASH Annual Meeting 2023 (GlobeNewswire)
Nov-01-23 05:58AM	Biomea Fusion Inc (BMEA) Reports Q3 2023 Financial Results and Corporate Highlights (GuruFocus.com)
Oct-31-23 01:19AM	The Biomea Fusion Inc (BMEA) Company: A Short SWOT Analysis (GuruFocus.com) -7.59%
Oct-30-23 04:01PM	Biomea Fusion Reports Third Quarter 2023 Financial Results and Corporate Highlights (GlobeNewswire)
Oct-18-23 10:13AM	Biomea (BMEA) Doses First Patient in Leukemia Study, Stock Up (Zacks)
Oct-17-23 08:30AM	Biomea Fusion Announces First Patient Dosed with Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia in Phase I Clinical Trial (COVALENT-103) (GlobeNewswire) +6.72%
Oct-05-23 09:40AM	Is Ayr Wellness Inc. (AYRWF) Outperforming Other Medical Stocks This Year? (Zacks)
08:30AM	Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for BMF-219 in Type 1 Diabetes (GlobeNewswire)
Sep-28-23 08:30AM	Biomea Fusion Announces FDA and Health Canada Clearance of the Expansion Cohorts of the Ongoing COVALENT-111 Phase II Study (GlobeNewswire)
Aug-31-23 08:30AM	Biomea Fusion Announces Appointment of Juan Pablo Frías, M.D. as Chief Medical Officer (GlobeNewswire)
Aug-23-23 12:26PM	11 Best High Short Interest Stocks To Buy Now (Insider Monkey)
Jul-31-23 04:01PM	Biomea Fusion Reports Second Quarter 2023 Financial Results and Corporate Highlights (GlobeNewswire) -6.70%
Jul-24-23 09:00AM	BMF-219 Induces Complete Responses in Target Acute Myeloid Leukemia (AML) Patient Population (GlobeNewswire) -14.58%
Jul-13-23 10:08AM	We Think Biomea Fusion (NASDAQ:BMEA) Needs To Drive Business Growth Carefully (Simply Wall St.)
Jun-26-23 10:54AM	Biomea Fusion Stock Is Trading Higher Today - Here's Why (Benzinga) -20.39%
Jun-23-23 09:54PM	Biomea Fusion Presents Positive Clinical Data from the Initial Cohorts of the Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes Mellitus at the American Diabetes Association (ADA) 83rd Scientific Sessions; 100 mg Cohort 3 Demonstrated a 90% Response Rate and 70% Maintained or Improved Time in (Normal Glucose) Range, While Off-Treatment (GlobeNewswire) -5.89%
Jun-20-23 04:30PM	Biomea Fusion to Present Late Breaking Data from Ongoing Phase II Trial, COVALENT-111, Evaluating BMF-219 in Patients with Type 2 Diabetes at ADA 2023 (GlobeNewswire)
Jun-05-23 06:44AM	Daily Vickers Top Buyers & Sellers for 06/05/2023 (Argus Research)
May-18-23 06:39AM	Daily Vickers Top Buyers & Sellers for 05/18/2023 (Argus Research)
May-14-23 09:43AM	TipRanks Perfect 10 List: 3 Top-Rated Stocks That Tick All the Right Boxes (TipRanks)
May-11-23 08:39AM	Top Healthcare Stocks for May 2023 (Investopedia)
May-02-23 04:01PM	Biomea Fusion Reports First Quarter 2023 Financial Results and Corporate Highlights (GlobeNewswire) -8.55% +5.76%
May-01-23 08:30AM	Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia (GlobeNewswire) +7.60%
Apr-27-23 07:02AM	Daily Vickers Top Buyers & Sellers for 04/27/2023 (Argus Research) -8.20%
Apr-23-23 09:28AM	individual investors who own 31% along with institutions invested in Biomea Fusion, Inc. (NASDAQ:BMEA) saw increase in their holdings value last week (Simply Wall St.)
Apr-19-23 02:42PM	Top Biotech Stocks for Q2 2023 (Investopedia) +5.77%
08:30AM	Biomea Fusion to Present Late Breaking Data from Ongoing Phase II Trial, COVALENT-111, Evaluating BMF-219 in Patients with Type 2 Diabetes, at the ADA 83rd Scientific Sessions 2023 in June (GlobeNewswire)
Apr-13-23 04:30PM	Biomea Fusion To Present Two Preclinical Posters at the 114th AACR Annual Meeting (GlobeNewswire) -7.20%
09:00AM	Biomea Fusion Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares (GlobeNewswire)

Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic disorders, such as diabetes. It offers its lead product candidate, BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The company was founded by Thomas Butler and Ramses Erdtmann in August 2017 and is headquartered in Redwood City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hitchcock Michael J.M.	Director	Sep 30 '24	Buy	10.06	10,000	100,600	15,000	Oct 01 04:30 PM
Valle Franco	Chief Financial Officer	Jun 11 '24	Buy	4.43	12,509	55,361	42,500	Jun 12 04:30 PM

HLXB

Helix Acquisition Corp. II

MLTX

MoonLake Immunotherapeutics

BMEA

Biomea Fusion Inc

Upgrade your FINVIZ experience